Announcements

Theravance Biopharma, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 11, 2026, covering the period ended June 30, 2026, and disclosing a net loss of $10.831 million for the first half of the year alongside …

Smithfield Foods, Inc. filed its Form 10-Q for the quarterly period ended June 28, 2026 with the U.S. Securities and Exchange Commission on August 11, 2026, disclosing income statements, balance sheet data, and cash flow results for the three and six months ended June …

Prelude Therapeutics Incorporated filed its Form 10-Q for the quarterly period ended June 30, 2026, with the U.S. Securities and Exchange Commission, reporting its first period of recognized revenue alongside a narrowed net loss compared to the prior year.

Cardinal Health, Inc. filed a Form 8-K on August 11, 2026, reporting that on August 7, 2026, the company entered into a new $4.0 billion unsecured revolving credit agreement and simultaneously terminated three prior credit and receivables facilities.

Cardinal Health, Inc. filed its Form 10-K for the fiscal year ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 11, 2026, covering operations across its Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution segments.

Cardinal Health, Inc. filed a Form 8-K with the SEC on August 11, 2026, announcing its financial results for the quarter and fiscal year ended June 30, 2026, and disclosing a webcast during which management will also discuss the fiscal year 2027 outlook.

Investors Title Company filed its Form 10-Q for the quarterly period ended June 30, 2026 with the Securities and Exchange Commission, reporting net income of $14,633 thousand for the second quarter and $20,700 thousand for the first six months of the year.